JP2015524444A - ライソゾーム蓄積症を治療するためのシクロデキストリン - Google Patents

ライソゾーム蓄積症を治療するためのシクロデキストリン Download PDF

Info

Publication number
JP2015524444A
JP2015524444A JP2015525640A JP2015525640A JP2015524444A JP 2015524444 A JP2015524444 A JP 2015524444A JP 2015525640 A JP2015525640 A JP 2015525640A JP 2015525640 A JP2015525640 A JP 2015525640A JP 2015524444 A JP2015524444 A JP 2015524444A
Authority
JP
Japan
Prior art keywords
cyclodextrin
disease
subject
compound
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015525640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524444A5 (https=
Inventor
ジョン マッキュー，
ジョン マッキュー，
ウェイ チョン，
ウェイ チョン，
ミャオ シュウ，
ミャオ シュウ，
マンジュ スワループ，
マンジュ スワループ，
ジュアン ジェイ． マルガン，
ジュアン ジェイ． マルガン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2015524444A publication Critical patent/JP2015524444A/ja
Publication of JP2015524444A5 publication Critical patent/JP2015524444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Materials Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015525640A 2012-08-03 2013-08-03 ライソゾーム蓄積症を治療するためのシクロデキストリン Pending JP2015524444A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679668P 2012-08-03 2012-08-03
US61/679,668 2012-08-03
PCT/US2013/053527 WO2014022841A1 (en) 2012-08-03 2013-08-03 Cyclodextrin for the treatment of lysosomal storage diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018116666A Division JP2018162277A (ja) 2012-08-03 2018-06-20 ライソゾーム蓄積症を治療するためのシクロデキストリン

Publications (2)

Publication Number Publication Date
JP2015524444A true JP2015524444A (ja) 2015-08-24
JP2015524444A5 JP2015524444A5 (https=) 2016-09-23

Family

ID=49170855

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015525640A Pending JP2015524444A (ja) 2012-08-03 2013-08-03 ライソゾーム蓄積症を治療するためのシクロデキストリン
JP2018116666A Pending JP2018162277A (ja) 2012-08-03 2018-06-20 ライソゾーム蓄積症を治療するためのシクロデキストリン
JP2020026808A Active JP6858286B2 (ja) 2012-08-03 2020-02-20 ライソゾーム蓄積症を治療するためのシクロデキストリン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018116666A Pending JP2018162277A (ja) 2012-08-03 2018-06-20 ライソゾーム蓄積症を治療するためのシクロデキストリン
JP2020026808A Active JP6858286B2 (ja) 2012-08-03 2020-02-20 ライソゾーム蓄積症を治療するためのシクロデキストリン

Country Status (7)

Country Link
US (2) US20150216895A1 (https=)
EP (1) EP2879714B1 (https=)
JP (3) JP2015524444A (https=)
CN (2) CN107865968B (https=)
AU (2) AU2013296170A1 (https=)
CA (1) CA2880880C (https=)
WO (1) WO2014022841A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018199287A1 (ja) * 2017-04-28 2018-11-01 国立大学法人京都大学 クリスタリン網膜症の処置および／または予防方法
JP2020176063A (ja) * 2019-04-15 2020-10-29 国立大学法人 熊本大学 ライソゾーム病の治療または予防のための医薬組成物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
WO2015083736A1 (ja) 2013-12-05 2015-06-11 国立大学法人熊本大学 コレステロール蓄積疾患治療薬、およびそのスクリーニング方法
US10413517B2 (en) 2014-06-12 2019-09-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CN107949380B (zh) * 2015-02-11 2021-07-06 西奈山伊坎医学院 用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
EP3405501B1 (en) * 2016-01-21 2023-11-15 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3515501A1 (en) 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2019067145A1 (en) * 2017-08-28 2019-04-04 Asdera Llc USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION
KR20200107927A (ko) * 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
BR112021008139A2 (pt) 2018-10-29 2021-08-03 Cyclo Therapeutics, Inc. métodos para tratar doença de alzheimer
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
JP7551339B2 (ja) * 2020-06-04 2024-09-17 株式会社三共 遊技機
JP7551340B2 (ja) * 2020-06-04 2024-09-17 株式会社三共 遊技機
WO2022051631A1 (en) * 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504166A (ja) * 2003-08-29 2007-03-01 バイオマリン ファーマシューティカル インコーポレイテッド 脳およびその他の組織への治療用化合物の送達
WO2012012473A1 (en) * 2010-07-19 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5262404A (en) 1990-02-15 1993-11-16 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
EP0803243B1 (en) 1996-04-24 2003-03-19 Pfizer Inc. Cyclodextrins and phenolic compounds in dental products
FR2767834B1 (fr) 1997-08-29 1999-12-03 Inst Francais Du Petrole Mono et di-derives de cyclodextrines, leurs synthese et purification et leur utilisation en support
AU2001259725A1 (en) 2000-05-15 2001-11-26 The Procter And Gamble Company Compositions comprising cyclodextrin derivatives
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
EP2433650A3 (en) * 2006-06-06 2012-12-19 Tolerrx Inc. Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
WO2010138802A2 (en) * 2009-05-28 2010-12-02 Cornell University Compositions and their use for removing cholesterol
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
FR3014694B1 (fr) 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504166A (ja) * 2003-08-29 2007-03-01 バイオマリン ファーマシューティカル インコーポレイテッド 脳およびその他の組織への治療用化合物の送達
WO2012012473A1 (en) * 2010-07-19 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. 5, no. 11, JPN6017022007, 2010, pages 15054 - 15054, ISSN: 0003579244 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018199287A1 (ja) * 2017-04-28 2018-11-01 国立大学法人京都大学 クリスタリン網膜症の処置および／または予防方法
JPWO2018199287A1 (ja) * 2017-04-28 2020-03-12 国立大学法人京都大学 クリスタリン網膜症の処置および／または予防方法
JP2020176063A (ja) * 2019-04-15 2020-10-29 国立大学法人 熊本大学 ライソゾーム病の治療または予防のための医薬組成物
JP7264452B2 (ja) 2019-04-15 2023-04-25 塩水港精糖株式会社 ライソゾーム病の治療または予防のための医薬組成物

Also Published As

Publication number Publication date
CN107865968A (zh) 2018-04-03
US20150216895A1 (en) 2015-08-06
JP2020097620A (ja) 2020-06-25
US20180110798A1 (en) 2018-04-26
EP2879714B1 (en) 2021-04-14
CA2880880C (en) 2021-01-26
AU2018202964A1 (en) 2018-05-17
CN104684585A (zh) 2015-06-03
US11020422B2 (en) 2021-06-01
EP2879714A1 (en) 2015-06-10
AU2018202964B2 (en) 2019-08-22
JP6858286B2 (ja) 2021-04-14
CA2880880A1 (en) 2014-02-06
WO2014022841A1 (en) 2014-02-06
JP2018162277A (ja) 2018-10-18
AU2013296170A1 (en) 2015-03-12
CN107865968B (zh) 2021-03-05
HK1210960A1 (en) 2016-05-13

Similar Documents

Publication Publication Date Title
JP6858286B2 (ja) ライソゾーム蓄積症を治療するためのシクロデキストリン
Gref et al. Vitamin C–squalene bioconjugate promotes epidermal thickening and collagen production in human skin
Zhou et al. Enhancement of the p38 MAPK and PKA signaling pathways is associated with the pro-melanogenic activity of Interleukin 33 in primary melanocytes
Itoh et al. Inhibitory effects of Citrus hassaku extract and its flavanone glycosides on melanogenesis
JP7042260B2 (ja) 皮膚炎症または老化を改善する新規のオートファジー作用活性化誘導化合物
JP6932386B2 (ja) 新しいカリクレイン７阻害剤
CA3163745A1 (en) Therapeutic compounds for methods of use in insulin resistance
JP2017505299A5 (https=)
EP3197460B1 (fr) Utilisation dermocosmetique ou pharmaceutique d'une composition contenant au moins un inhibiteur de certaines chimiokines
KR102773595B1 (ko) 세노모르픽스용 또는 피부 노화 방지용 조성물
US20090170788A1 (en) Novel use of 1, 2, 3, 4, 6-penta-o-galloyl-beta-d-glucose
WO2018199287A1 (ja) クリスタリン網膜症の処置および／または予防方法
JP5700340B2 (ja) 皮膚の炎症または傷害の予防または抑制剤
HK1210960B (en) Cyclodextrin for the treatment of lysosomal storage diseases
BRPI0617938A2 (pt) utilização de uma quantidade eficaz de pelo menos uma substáncia modulando a expressão e/ou atividade de lox e de um anticorpo anti-nrage, métodos de utilização e de identificação de pelo menos um princìpio ativo destinado a modular a interação entre lox e nrage e de localização de nrage e processo de preparação de uma composição
JP2004083432A (ja) エラスターゼ阻害剤
US20230126139A1 (en) HETEROCYCLIC INHIBITORS OF RHO GTPases FOR THE TREATMENT OF DISEASE
JP2003155231A (ja) 医薬及び抗アレルギー剤
EP4609848A1 (en) Method for obtaining a composition comprising crude water extract of galega officinalis l. water, hippophae rhamnoides oil and resveratrol
KR20090052096A (ko) 이끼 추출물 또는 그 유효 성분인 뎁시돈 또는 뎁시돈유도체를 함유하는 항노화 피부 외용제 조성물
KR102895957B1 (ko) 노화세포 회춘용 조성물 및 노화세포 회춘방법
KR20250075999A (ko) 염증의 예방 또는 치료용 약학 조성물 및 염증 또는 피부노화 개선용 화장료 조성물
KR20210093061A (ko) 노화세포 회춘용 조성물 및 노화세포 회춘방법
Zhao et al. Endothelial prolyl hydroxylase 2 is necessary for Angiotensin II-mediated renal fibrosis
JPH02138985A (ja) 脂肪酸含有脂質の製造方法とそれを含有する色白剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180220